ECSP22050840A - Nuevos compuestos farmac?uticos - Google Patents

Nuevos compuestos farmac?uticos

Info

Publication number
ECSP22050840A
ECSP22050840A ECSENADI202250840A ECDI202250840A ECSP22050840A EC SP22050840 A ECSP22050840 A EC SP22050840A EC SENADI202250840 A ECSENADI202250840 A EC SENADI202250840A EC DI202250840 A ECDI202250840 A EC DI202250840A EC SP22050840 A ECSP22050840 A EC SP22050840A
Authority
EC
Ecuador
Prior art keywords
pharmaceutical compounds
new pharmaceutical
new
tuberculosis
prevention
Prior art date
Application number
ECSENADI202250840A
Other languages
English (en)
Inventor
Pedro Silva Serra Joao
Patricia Da Costa Pereira Rosa Carla
Ferreira Ana L?Cia Almeida
Carlos Ramos Damil Joao
Homem E Sousa Dos Santos Sara Alexandra Marques
Vanessa Cordeiro Simoes Ana
Neves Rita Isabel Gomes
Filipe Augusto Eugenio Pardal
Original Assignee
Tecnimede Soc T?Cnico Medicinal Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tecnimede Soc T?Cnico Medicinal Sa filed Critical Tecnimede Soc T?Cnico Medicinal Sa
Publication of ECSP22050840A publication Critical patent/ECSP22050840A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Quinoline Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente divulgaci?n se refiere a derivados de 6-sustituida quinolina-2-piperidina para su uso en el tratamiento y/o la prevenci?n de la tuberculosis.
ECSENADI202250840A 2019-12-27 2022-07-04 Nuevos compuestos farmac?uticos ECSP22050840A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PT11602819 2019-12-27
PT11616820 2020-03-13
EP20163200 2020-03-13
PCT/IB2020/062483 WO2021130732A1 (en) 2019-12-27 2020-12-28 Antibacterial quinolines

Publications (1)

Publication Number Publication Date
ECSP22050840A true ECSP22050840A (es) 2022-08-31

Family

ID=74554188

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202250840A ECSP22050840A (es) 2019-12-27 2022-07-04 Nuevos compuestos farmac?uticos

Country Status (19)

Country Link
US (1) US12383548B2 (es)
EP (1) EP4081304B1 (es)
JP (1) JP7611255B2 (es)
KR (1) KR20220122649A (es)
CN (1) CN114867528B (es)
AU (1) AU2020414492A1 (es)
BR (1) BR112022012704A2 (es)
CA (1) CA3162532A1 (es)
CL (1) CL2022001736A1 (es)
CO (1) CO2022009810A2 (es)
EC (1) ECSP22050840A (es)
GE (1) GEP20247590B (es)
IL (1) IL294363B2 (es)
MX (1) MX2022008005A (es)
PE (1) PE20221725A1 (es)
PH (1) PH12022551392A1 (es)
SA (1) SA522433149B1 (es)
WO (1) WO2021130732A1 (es)
ZA (1) ZA202208089B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4296674A1 (en) 2022-06-20 2023-12-27 Université Toulouse III - Paul Sabatier Innovative molecules decreasing virulence of mycobacterium for the treatment of tuberculosis
CN116326587A (zh) * 2023-03-30 2023-06-27 西南大学 氧烷酰基克林沙星衍生物在制备抗柑橘溃疡病菌药物中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4425612A1 (de) * 1994-07-20 1996-04-04 Bayer Ag 6-gliedrige stickstoffhaltige Heteroaryl-oxazolidinone
DK1527050T3 (da) 2002-07-25 2010-07-19 Janssen Pharmaceutica Nv Quinolin-derivater og deres anvendelse som mycobakterielle inhibitorer
CA2592118C (en) * 2004-12-23 2015-11-17 Deciphera Pharmaceuticals, Llc Urea derivatives as enzyme modulators
US7868022B2 (en) 2006-02-06 2011-01-11 Janssen Pharmaceutica Nv 2-amino-quinoline derivatives useful as inhibitors of β-secretase (BACE)
CN101784276A (zh) * 2007-06-27 2010-07-21 传染性疾病研究院 化合物在用于制备抗结核药剂中的用途
CA2717453A1 (en) 2008-03-07 2009-09-11 F. Hoffmann-La Roche Ag 2-aminoquinolines
CA2805932A1 (en) 2010-08-27 2012-03-01 Gruenenthal Gmbh Substituted 2-amino-quinoline-3-carboxamides as kcnq2/3 modulators
US20160113919A1 (en) 2014-10-22 2016-04-28 The Board Of Trustees Of The Leland Stanford Junior University Chloroquine stereoisomer for treating tuberculosis related diseases
BR112017028318B1 (pt) 2015-07-02 2024-02-20 Janssen Sciences Ireland Uc Composto antibacteriano, seu uso, processo para sua preparação,produto que o contém, composição farmacêutica e combinação
US10329257B2 (en) 2015-08-13 2019-06-25 The Broad Institute, Inc. Compositions and methods for treating tuberculosis
US9856208B2 (en) * 2015-09-03 2018-01-02 The Royal Institution For The Advancement Of Learning/Mcgill University Method for producing an arene with an aromatic C—N bond ortho to an aromatic C—O bond
WO2019243971A1 (en) * 2018-06-17 2019-12-26 Foundation For Neglected Disease Research Novel compounds and their methods of use thereof

Also Published As

Publication number Publication date
IL294363B2 (en) 2025-09-01
WO2021130732A1 (en) 2021-07-01
US20230106913A1 (en) 2023-04-06
EP4081304C0 (en) 2024-03-06
JP7611255B2 (ja) 2025-01-09
PE20221725A1 (es) 2022-11-04
AU2020414492A1 (en) 2022-08-18
CA3162532A1 (en) 2021-07-01
CN114867528A (zh) 2022-08-05
GEP20247590B (en) 2024-02-12
JP2023508475A (ja) 2023-03-02
CL2022001736A1 (es) 2023-02-17
KR20220122649A (ko) 2022-09-02
US12383548B2 (en) 2025-08-12
BR112022012704A2 (pt) 2022-09-06
IL294363A (en) 2022-08-01
CN114867528B (zh) 2024-03-19
SA522433149B1 (ar) 2025-04-20
EP4081304A1 (en) 2022-11-02
IL294363B1 (en) 2025-05-01
PH12022551392A1 (en) 2023-09-25
ZA202208089B (en) 2024-01-31
CO2022009810A2 (es) 2022-08-09
EP4081304B1 (en) 2024-03-06
MX2022008005A (es) 2022-07-21

Similar Documents

Publication Publication Date Title
DOP2019000005A (es) 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2
SV2018005610A (es) Derivados de oxopiridina sustituidos
MX381041B (es) Compuesto cíclico tipo cumarina como inhibidor de mek y su uso.
SV2015005115A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
MX2019012847A (es) Compuestos de c5-anilinoquinazolina y su uso en el tratamiento del cancer.
MX2020011104A (es) Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso.
UY37645A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
CO2018004857A2 (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer
CO2018008421A2 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
CR11684A (es) Dihidropirazolonas sustituidas de hif-propil-4- como inhibidores hidroxilasa
UY37646A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
CL2015003357A1 (es) Derivados de nucleósidos 4'-fluoro-2'-metil sustituidos
MX2020013320A (es) Inhibidores de ectonucleotidasa y métodos de uso de los mismos.
UY37742A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
UY35344A (es) Oestra-1,3,5(10),16-tetraeno-3-carboxamidas
MX2017013137A (es) Derivados de cromeno como inhibidores de las fosfoinositido-3-cina sas.
MX388378B (es) Compuestos de aza-indazol para usar en lesiones de tendones y/o ligamentos.
MX2021015770A (es) Inhibidores macrociclicos de mcl-1.
DOP2016000297A (es) Composiciones farmacéuticas útiles para tratar enfermedades infecciosas
CL2016002151A1 (es) Derivados de piridazina para uso en la prevención o el tratamiento de un trastorno atáxico
CL2019002480A1 (es) Derivados de pirazol como inhibidores de bromodominio.
MX2019012522A (es) Compuestos y metodos terapeuticos.
ECSP22050840A (es) Nuevos compuestos farmac?uticos
UY37729A (es) NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7
UY37671A (es) N-ariletil-2-aminoquinolin-4-carboxamidas sustituidas y su uso